Cargando…

PB2430: EVALUATION OF OUTCOME AND SAFETY PROFILE IN HIGH-DOSE BEAM AND BEEAM CHEMOTHERAPY WITH SUBSEQUENT AUTOLOGOUS STEM CELL TRANSPLANTATION IN LYMPHOMA PATIENTS – SINGLE-CENTER EXPERIENCE

Detalles Bibliográficos
Autores principales:	Krawiec, Kinga, Strzałka, Piotr, Mikulski, Damian, Kośny, Michał, Racińska, Olga, Sowul, Hubert, Kędzior, Marcin, Salamon, Wojciech, Czemerska, Magdalena, Pluta, Agnieszka, Wierzbowska, Agnieszka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428699/ http://dx.doi.org/10.1097/01.HS9.0000976428.88168.ef

Ejemplares similares

P551: EVALUATION OF PROGNOSTIC FACTORS FOR SURVIVAL AND TREATMENT OUTCOMES OF PATIENTS WITH SECONDARY ACUTE MYELOID LEUKEMIA – A SINGLE-CENTER STUDY
por: Strzałka, Piotr, et al.
Publicado: (2023)

Targeting Apoptosis in AML: Where Do We Stand?
por: Krawiec, Kinga, et al.
Publicado: (2022)

High serum miR-223-3p expression level predicts complete response and prolonged overall survival in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation
por: Mikulski, Damian, et al.
Publicado: (2023)

Evaluation of Bortezomib-BeEAM (2BeEAM) as Chemotherapy Regimen Prior to ASCT in Patients with Mantle Cell Lymphoma
por: Huwyler, Fabrizio, et al.
Publicado: (2023)

BeEAM High-Dose Chemotherapy with Polatuzumab (Pola-BeEAM) before ASCT in Patients with DLBCL—A Pilot Study
por: Stoffel, Tanja, et al.
Publicado: (2022)

Observation of D$_{1}$(2430)$^{+}$ and D$_{2}^{*}$(2470) $^{+}$
por: Butler, F, et al.
Publicado: (1994)

2430: Leading diverse and emerging scientists to success (LEADS)
por: Rubio, Doris, et al.
Publicado: (2018)

P1535: ASSESSMENT OF COLONIZATION AND INFECTION EPIDEMIOLOGY IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION – A PROSPECTIVE MULTI-CENTER STUDY OF POLISH ADULT LEUKEMIA GROUP (PALG).
por: Pluta, Agnieszka, et al.
Publicado: (2023)

Alterations in microRNA Expression during Hematopoietic Stem Cell Mobilization
por: Nowicki, Mateusz, et al.
Publicado: (2021)

The role of NF-κB and Smac/DIABLO proteins in the treatment response and survival of acute myeloid leukemia patients
por: Pluta, Agnieszka, et al.
Publicado: (2019)

BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia
por: Heini, Alexander D., et al.
Publicado: (2023)

PB1964: RELATIONSHIP BETWEEN SIRT1-7 AND SELECTED MIRNAS EXPRESSIONS IN MYELOMA/LYMPHOMA PATIENTS IN DIFFERENT REMISSION STATUS.
por: Nowicki, M., et al.
Publicado: (2022)

PB2066: SYSTEMIC LUPUS ERYTHEMATOSUS-INDUCED AMEGAKARYOCYTIC THROMBOCYTOPENIA AND SUBSEQUENT APLASTIC ANEMIA
por: Seong, Gyuhee, et al.
Publicado: (2023)

2430. Comorbidity and Severity of Illness Risk Adjustment for Hospital-Onset Clostridioides difficile Infection
por: Cabral, Stephanie, et al.
Publicado: (2019)

Combining BeEAM with Brentuximab Vedotin for High-Dose Therapy in CD30 Positive Lymphomas before Autologous Transplantation—A Phase I Study
por: Rausch, Christian, et al.
Publicado: (2022)

PB2448: RESTORATION OF HEMOGRAM PARAMETERS IN PATIENTS WITH HEMOBLASTOSIS AFTER TRANSPLANTATION OF AUTOLOGOUS HEMATOPOIETIC STEM CELLS
por: Natalia, Isaeva, et al.
Publicado: (2023)

PB2316: SAFETY AND EFFICACY OF AUTOLOGOUS HSCT IN NINE PATIENTS WITH AIDS-RELATED NON-HODGKIN LYMPHOMA
por: Liu, Jun, et al.
Publicado: (2023)

PB2453: FACTORS INFLUENCING AUTOLOGOUS PERIPHERAL BLOOD STEM CELL MOBILIZATION IN LYMPHOMA AND MULTIPLE MYELOMA
por: Longrong, Ran, et al.
Publicado: (2023)

BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy
por: Hahn, Logan, et al.
Publicado: (2021)

PB2193: IS HYPERHYDRATION NECESSARY FOR HIGH DOSE MELPHALAN CONDITIONING REGIMEN IN AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION?
por: Mora Argumánez, M., et al.
Publicado: (2022)

PB2007: FACTORS ASSOCIATED WITH EARLY RELAPSE IN MYELOMA PATIENTS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Karatas, A., et al.
Publicado: (2022)

PB1977: SPECTRUM OF INFECTIOUS COMPLICATIONS FOLLOWING TRANSPLANTATION OF AUTOLOGOUS BLOOD STEM CELLS IN PATIENTS WITH MULTIPLE MYELOMA
por: Abakumova, A., et al.
Publicado: (2022)

PB2102: IMPACT OF AUTOLOGOUS STEM CELL TRASPLANTATION IN AL AMYLOIDOSIS. EXPERIENCE IN A SINGLE TERTIARY HOSPITAL
por: Alonso, Elena Alejo, et al.
Publicado: (2023)

PB2415: THE ROLE OF NUTRITIONAL SUPPORT DURING AUTOLOGOUS STEM CELL TRANSPLANTATION (AUTOHSCT) IN PATIENTS WITH HODGKIN LYMPHOMA.
por: Volchenkov, Stanislav, et al.
Publicado: (2023)

PB2182: CHARACTERISTICS THAT INFLUENCE THE STEM CELL COLLECTION BY APHERESIS IN PATIENTS WHO ARE CANDIDATES FOR AUTOLOGOUS STEM CELL TRANSPLANTATION
por: Garzón, K., et al.
Publicado: (2022)

PB2419: THE OUTCOME OF VIRAL HEPATITIS-C INFECTION ON HEMATOLOGICAL MALIGNANCIES AFTER AUTOLOGOUS BONE MARROW TRANSPLANTATION IN EGYPT
por: Elashwah, Salma, et al.
Publicado: (2023)

Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation
por: Frankiewicz, Andrzej, et al.
Publicado: (2018)

Draft Genome Sequence of Amycolatopsis lurida NRRL 2430, Producer of the Glycopeptide Family Antibiotic Ristocetin
por: Kwun, Min Jung, et al.
Publicado: (2014)

PB2463: PROTRACTED DIARRHEA FROM HIGH-DOSE MELPHALAN IN AUTOLOGOUS HEMATOPOIETIC TRANSPLANTATION: RESPONSE TO SHORT COURSE OF ORAL BUDESONIDE
por: Kamble, Rammurti, et al.
Publicado: (2023)

PB2033: INFLUENCE OF INDUCTION THERAPY WITH LENALIDOMIDE ON MAINTENANCE THERAPY AND PROGNOSIS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
por: Sun, Q., et al.
Publicado: (2022)

PB1978: AUTOLOGOUS STEM CELL TRANSPLANTATION AND MAINTENANCE IMPROVES SURVIVAL, IN COLOMBIAN MULTIPLE MYELOMA PATIENTS. ACHO’S RENEHOC REGISTRY REPORT
por: Abello, V., et al.
Publicado: (2022)

PB2411: THE EFFICACY OF MODIFIED MELPHALAN AND BUSULFAN-BASED CONDITIONING REGIMEN FOR AUTOLOGOUS-HSCT IN LOW-RISK AND INTERMEDIATE-RISK AML PATIENTS
por: Zhai, Weihua, et al.
Publicado: (2023)

PB2456: SURVIVAL OF MULTIPLE MYELOMA PATIENTS YOUNGER AND OLDER THAN 60 YEARS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Kostroma, Ivan, et al.
Publicado: (2023)

Z-BeEAM (Ibritumomab tiuxetan, Bendamustine, Etoposide, Cytarabine, Melphalan) before autologous stem cell transplantation is safe and efficient for refractory large B-cell lymphoma
por: Tardy, Magalie P., et al.
Publicado: (2015)

PB1982: DEEPENING OF RESPONSE IN PATIENTS WITH MULTIPLE MYELOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION: A MULTICENTRIC STUDY IN A LATINO POPULATION
por: Bourlon, C., et al.
Publicado: (2022)

PB2449: EFFECT OF MOBILIZATION METHODS ON CD34+ AND TOTAL NUCLEATED CELL COUNT AND THEIR RELATION WITH ENGRAFTMENT IN AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Beyler, Ozlem, et al.
Publicado: (2023)

PB2416: EFFICACY AND SAFETY OF BIOSIMILAR PEGFILGRASTIM AFTER AUTOLOGOUS STEM CELL TRANSPLANT: A COMPARATIVE STUDY WITH BIOSIMILAR FILGRASTIM, LENOGRASTIM AND ORIGINATOR PEGFILGRASTIM
por: Marchesi, Francesco, et al.
Publicado: (2023)

PB2339: CLINICAL OUTCOMES OF RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: THE ROLE OF AUTOLOGOUS STEM-CELL TRANSPLANTATION IN AN INTEND TO TREAT POPULATION
por: Mesquita, Isabel Paulos, et al.
Publicado: (2023)

PB2440: AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN LYMPHOMA: A 10-YEAR REVIEW OF ACTIVITY AT THE TUNISIAN NATIONAL BONE MARROW TRANSPLANTATION CENTER
por: Ben Yaiche, Insaf, et al.
Publicado: (2023)

PB2436: EFFICACY AND SAFETY PROFILE OF EVEROLIMUS AS A MAINTENANCE THERAPY FOR PRIMARY REFRACTORY/RELAPSING HODGKIN LYMPHOMA FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Zamani, Shayan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6nna4h5hf449u9iccm15enftnc